Representative Experience

Representing a collection of leading academic medical centers and manufacturers of medical devices in their efforts to obtain coverage and reimbursement for a leading biotechnology company and cancer center

Foley Hoag is presently representing leading pharmaceutical and biotechnology companies in connection with legislative efforts to provide a prescription drug benefit for Medicare beneficiaries

Represented a leading biotechnology company in increasing hospital outpatient reimbursement for supportive anti-cancer therapy

Represented a collection of leading academic medical centers and manufacturers of medical devices in their efforts to obtain coverage and reimbursement for new diagnostic imaging technology

Foley Hoag has represented our clients on issues related to drug pricing and reform of the Average Wholesale Price (AWP) for drugs

Represented a leading pharmaceutical manufacturer in achieving unprecedented coverage of an oral drug under Medicare Part B

Provided counsel to a leading biotechnology company and cancer center in obtaining a DRG reclassification for hospital inpatient reimbursement for therapy for renal cell carcinoma and melanoma

Worked to include language in the Medicare, Medicaid and SCHIP Benefits Improvement Act of 2000 (BIPA) that amended the rules regarding coverage of self-administered drugs. This legislation was enacted, and Foley Hoag continued to work with CMS to implement related regulations under BIPA.

We are involved in issues related to "Hatch-Waxman" patent-term issues

Advising a leading biotechnology company and cancer center in obtaining adequate hospital inpatient reimbursement for its IL-2 therapy for renal cell carcinoma and melanoma

Expanded coverage of leading therapy for the treatment of age-related macular degeneration, which had been previously non-covered

In connection with the reauthorization of the Prescription Drug User Fee Act and the Public, Health, Security and Bioterrorism Preparedness and Response Act, Foley Hoag represented several leading pharmaceutical and biotechnology companies and industry trade associations

We represented clients under the Orphan Drug Act, which is credited with giving rise to the biotechnology industry, through its provision of seven years of marketing exclusivity to companies that develop drugs or biologics for patients with rare diseases